Healthcare innovations cannot happen without capital. It can take years – even decades – before a biotech company brings a new medication to market, while product-focused companies also need cash to carry out clinical trials and maintain operations. As demand for more innovative products increases, and with Canada’s pharmaceutical sector trying to assert itself as a major player in a highly competitive global industry, the need for financing has never been greater.
Companies in this sector need to tap into a variety of financing arrangements, including initial public offerings, series raises, debt offerings, royalty purchase agreements and more. They also need current information on regulatory matters related to corporate finance transactions, including advising on trading, registration, settlement and compliance issues.
These issues require an expert group that knows how to work with banks, pension funds, venture capital, private equity and other capital market players. Our Capital Markets Group has a solid track record advising on everything from private placements to public offerings to alternative listing methods such as reverse takeovers and CPC transactions. We have extensive experience with a wide variety of complex financing methods.
As this industry continues to evolve rapidly, finding the right financing to scale up your operations and ensure your discoveries come to market is key.